Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

EVP and Chief Medical Officer

SVP, Chief Accounting Officer

CBO & EVP

President & CEO

EVP & Chief Commercial Officer

See Remarks

Chief Financial Officer

EVP and Chief Legal Officer

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111 (ABO-102), an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercializatio...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-05-02	Premium	sold	Premium	Premium	Premium	EVP and Chief Medical Officer
2024-04-18	Premium	sold	Premium	Premium	Premium	EVP and Chief Medical Officer
2024-04-16	Premium	sold (taxes)	Premium	Premium	Premium	SVP, Chief Accounting Officer
2024-03-11	Premium	sold	Premium	Premium	Premium	CBO & EVP
2024-03-07	Premium	sold	Premium	Premium	Premium	-
2024-03-01	Premium	acquired	Premium	Premium	Premium	President & CEO
2024-03-01	Premium	sold	Premium	Premium	Premium	EVP and Chief Medical Officer
2024-03-01	Premium	sold	Premium	Premium	Premium	EVP & Chief Commercial Officer
2024-03-01	Premium	sold (taxes)	Premium	Premium	Premium	See Remarks
2024-03-01	Premium	sold (taxes)	Premium	Premium	Premium	SVP, Chief Accounting Officer
2024-03-01	Premium	sold (taxes)	Premium	Premium	Premium	President & CEO
2024-03-01	Premium	acquired	Premium	Premium	Premium	SVP, Chief Accounting Officer
2024-03-01	Premium	acquired	Premium	Premium	Premium	Chief Financial Officer
2024-03-01	Premium	sold (taxes)	Premium	Premium	Premium	See Remarks
2024-03-01	Premium	acquired	Premium	Premium	Premium	EVP & Chief Commercial Officer
2024-03-01	Premium	sold	Premium	Premium	Premium	CBO & EVP
2024-03-01	Premium	acquired	Premium	Premium	Premium	EVP and Chief Medical Officer
2024-03-01	Premium	acquired	Premium	Premium	Premium	EVP and Chief Legal Officer
2024-03-01	Premium	sold	Premium	Premium	Premium	EVP and Chief Legal Officer
2024-03-01	Premium	sold	Premium	Premium	Premium	SVP, Chief Accounting Officer
2024-03-01	Premium	sold	Premium	Premium	Premium	See Remarks
2024-03-01	Premium	acquired	Premium	Premium	Premium	See Remarks
2024-03-01	Premium	acquired	Premium	Premium	Premium	See Remarks
2024-03-01	Premium	acquired	Premium	Premium	Premium	CBO & EVP
2024-03-01	Premium	sold (taxes)	Premium	Premium	Premium	CBO & EVP

RARE - Ultragenyx Pharmaceutical Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for RARE